Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer, Other Indications |
| Therapuetic Areas: | Oncology, Other |
| Healthy: | No |
| Age Range: | 18 - 120 |
| Updated: | 5/4/2018 |
| Start Date: | February 1993 |
| End Date: | June 2021 |
Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA)
level, and cancer stage from patients who have undergone radiation therapy for prostate
cancer may help doctors predict how patients respond to treatment and help plan the best
treatment.
PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in
predicting outcome in patients who have undergone radiation therapy for localized prostate
cancer.
level, and cancer stage from patients who have undergone radiation therapy for prostate
cancer may help doctors predict how patients respond to treatment and help plan the best
treatment.
PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in
predicting outcome in patients who have undergone radiation therapy for localized prostate
cancer.
OBJECTIVES:
- Evaluate the value of the pre-operative Gleason score, prostate-specific antigen level,
and clinical stage in predicting the risk of failure and death in patients who have
undergone radiotherapy for localized prostate cancer.
OUTLINE: This is a multicenter study.
Patient medical records are reviewed to collect data about pre-treatment prostate biopsy,
assigned Gleason score, prostate-specific antigen level, and radionucleotide bone scan.
Patients complete a Bowel Toxicity questionnaire to assess quality of life related to acute
and long-term bowel toxicity after radiotherapy.
- Evaluate the value of the pre-operative Gleason score, prostate-specific antigen level,
and clinical stage in predicting the risk of failure and death in patients who have
undergone radiotherapy for localized prostate cancer.
OUTLINE: This is a multicenter study.
Patient medical records are reviewed to collect data about pre-treatment prostate biopsy,
assigned Gleason score, prostate-specific antigen level, and radionucleotide bone scan.
Patients complete a Bowel Toxicity questionnaire to assess quality of life related to acute
and long-term bowel toxicity after radiotherapy.
DISEASE CHARACTERISTICS:
- Diagnosis of localized adenocarcinoma of the prostate
- Has undergone radiotherapy (external beam radiotherapy and/or brachytherapy) with or
without hormonal therapy for adenocarcinoma of the prostate in the UCSF Radiation
Oncology Department at San Francisco General Hospital or Veterans Administration
Medical Center of San Francisco between 1987 and 2006
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
We found this trial at
1
site
1600 Divisadero Street
San Francisco, California 94115
San Francisco, California 94115
888.689.8273
Phone: 877-827-3222
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
Click here to add this to my saved trials
